Tridek-One

Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering. Our company is financed by leading...

Santé,healthcare,immunomodulation,monoclonal antibody,vasculatis,and anca

Tridek-one operates in the Biotechnology research industry.

Tridek-one's revenue is 1m - 10m

Tridek-one has 11 - 50 employees.